Improving outcomes in patients with non-tuberculous mycobacterial disease: is there light at the end of the tunnel?
作者信息
Dheda Keertan
机构信息
Centre for Lung Infection and Immunity, Division of Pulmonology, Dept of Medicine and UCT Lung Institute and South African MRC/UCT Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa
Faculty of Infectious and Tropical Diseases, Dept of Immunology and Infection, London School of Hygiene and Tropical Medicine, London, UK.
出版信息
Eur Respir J. 2019 Jul 11;54(1). doi: 10.1183/13993003.01149-2019. Print 2019 Jul.
PMID:31296786
Abstract
摘要
相似文献
1
Improving outcomes in patients with non-tuberculous mycobacterial disease: is there light at the end of the tunnel?改善非结核分枝杆菌病患者的治疗效果：曙光在望？
Eur Respir J. 2019 Jul 11;54(1). doi: 10.1183/13993003.01149-2019. Print 2019 Jul.
2
Clinical aspects of the Mycobacterium abscessus complexAuthors' replyClinical aspects in patients with pulmonary infection caused by mycobacteria of the Mycobacterium abscessus complex, in the Brazilian AmazonBurden of non-tuberculous mycobacterial pulmonary disease in GermanyBritish Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).脓肿分枝杆菌复合体的临床方面 作者回复 巴西亚马逊地区脓肿分枝杆菌复合体分枝杆菌引起的肺部感染患者的临床方面 德国非结核分枝杆菌肺病负担 英国胸科学会非结核分枝杆菌肺病（NTM-PD）管理指南
J Bras Pneumol. 2018 Sep-Oct;44(5):434-435. doi: 10.1590/S1806-37562018000000193.
3
Recent advances in nontuberculous mycobacterial lung infections.非结核分枝杆菌肺部感染的最新进展
F1000Res. 2019 Oct 1;8. doi: 10.12688/f1000research.20096.1. eCollection 2019.
4
Pulmonary : can we identify the road to improved outcomes?肺部疾病：我们能否找到改善治疗效果的途径？
Eur Respir J. 2019 Jul 11;54(1). doi: 10.1183/13993003.01121-2019. Print 2019 Jul.
5
Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.非结核分枝杆菌肺病由鸟分枝杆菌复合群和脓肿分枝杆菌复合群混合感染引起。
Antimicrob Agents Chemother. 2018 Sep 24;62(10). doi: 10.1128/AAC.01105-18. Print 2018 Oct.
6
Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?
Eur Respir J. 2019 Nov 28;54(5). doi: 10.1183/13993003.01806-2019. Print 2019 Nov.
7
Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?非结核分枝杆菌感染：没有药代动力学，会有药效动力学吗？
Eur Respir J. 2019 Nov 28;54(5). doi: 10.1183/13993003.01508-2019. Print 2019 Nov.
8
Antibiotic treatment for nontuberculous mycobacterial lung disease.非结核分枝杆菌肺病的抗生素治疗
Expert Rev Respir Med. 2016;10(5):557-68. doi: 10.1586/17476348.2016.1165611. Epub 2016 Mar 30.
9
An evaluation of methods for the isolation of nontuberculous mycobacteria from patients with cystic fibrosis, bronchiectasis and patients assessed for lung transplantation.评价从囊性纤维化、支气管扩张症患者以及进行肺移植评估的患者中分离非结核分枝杆菌的方法。
BMC Pulm Med. 2019 Jan 21;19(1):19. doi: 10.1186/s12890-019-0781-2.
10
Non-Tuberculous Mycobacteria multispecies biofilms in cystic fibrosis: development of an in vitro Mycobacterium abscessus and Pseudomonas aeruginosa dual species biofilm model.囊性纤维化中多种非结核分枝杆菌生物膜：体外脓肿分枝杆菌和铜绿假单胞菌双种生物膜模型的建立。
Int J Med Microbiol. 2018 Apr;308(3):413-423. doi: 10.1016/j.ijmm.2018.03.003. Epub 2018 Mar 6.
Zotero 插件